1.中国药科大学 药学院药物分析教研室,江苏 南京 210009
2.中国药科大学 药物科学研究院, 江苏 南京 210009
丁 娅,教授,研究方向:药物分析新材料和新技术,E-mail:dingya@cpu.edu.cn
沈文斌,研究员,研究方向:核磁共振,E-mail:13851545091@163.com
扫 描 看 全 文
胡炜琪,刘秋芬,丁娅等.奈玛特韦原料药含量的定量核磁共振法测定[J].分析测试学报,2023,42(07):876-881.
HU Wei-qi,LIU Qiu-fen,DING Ya,et al.Determination of Nirmatrelvir by Quantitative Nuclear Magnetic Resonance[J].Journal of Instrumental Analysis,2023,42(07):876-881.
胡炜琪,刘秋芬,丁娅等.奈玛特韦原料药含量的定量核磁共振法测定[J].分析测试学报,2023,42(07):876-881. DOI: 10.19969/j.fxcsxb.23022706.
HU Wei-qi,LIU Qiu-fen,DING Ya,et al.Determination of Nirmatrelvir by Quantitative Nuclear Magnetic Resonance[J].Journal of Instrumental Analysis,2023,42(07):876-881. DOI: 10.19969/j.fxcsxb.23022706.
建立了测定奈玛特韦原料药绝对含量的定量核磁共振氢谱法(,1,H qNMR)。基于奈玛特韦在溶液中的构象稳定条件,以DMSO-D,6,和D,2,O(5∶1,体积比)为溶剂,,δ,4.96(1H,dd)和,δ,4.67(1H,dd)处的质子信号作为奈玛特韦的定量峰,,δ,6.22(1H,t)和,δ,5.84(1H,d)为拉米夫定的内标峰。样品与内标摩尔比在0.5∶1.0 ~ 1.2∶1.0范围时的线性拟合方程为,Y,=0.456 4,X, - 0.000 5(,r,2, = 0.999 9),该方法专属性强,耐用性、重复性良好,回收率满足要求,稳定性可达48 h。该方法测得的奈玛特韦样品的含量为99.23%(相对标准偏差为0.24%)。,1,H qNMR法操作简单,具有无损、准确快速的特点,适用于新药奈玛特韦绝对含量的测定。
A quantitative nuclear magnetic resonance(,1,H qNMR) method was developed for the determination of the absolute content of nirmatrelvir API.Based on the conformationally stable conditions of nemativir in solution,the proton signals at ,δ,4.96(1H,dd),,δ,4.67(1H,dd) and ,δ,6.22(1H,t),,δ,5.84(1H,d) were selected as the quantitative peaks for nirmatrelvir and lamivudine respectively in DMSO-D,6, and D,2,O(5∶1,by volume) solvents on BRUKER AV-500 NMR instrument.The qNMR method exhibited a high specificity,and an linear fitting equation ,Y ,= 0.456 4,X ,- 0.000 5(,r,2, = 0.999 9) was obtained in the range of 0.5∶1.0-1.2∶1.0 for the molar ratio of sample to internal standard,and the results showed good durability,reproducibility,recovery and 48-hour stability.The content of nirmatrelvir was determined to be 99.23%(RSD = 0.24%) by qNMR.The ,1,H qNMR method is simple,non-destructive,accurate and rapid,which is suitable for determination on the absolute content of nirmatrelvir API.
奈玛特韦拉米夫定定量核磁共振法含量测定
nirmatrelvirlamivudinequantitative NMRcontent determination
Coronavirus(COVID-19) Update:FDA Authorizes First Oral Antiviral for Treatment of COVID-19. [2023-02-10].
Wang H,Zhang C.Clin. Med. J. (王欢,张铖.临床药物治疗杂志),2022,20(2):13-17.
FDA. Fact Sheet for Healthcare Providers:Emergency Use Authorization for PaxlovidTM. [2023-02-10].
Chen Y Y,Chen W.J. Jiangsu Univ.:Med. Ed. (陈洋洋,陈伟.江苏大学学报:医学版),2022,32(6):537-541,545.
Hung Y P,Lee J C,Chiu C W,Lee C C,Tsai P J,Hsu I L,Ko W C.Antibiotics (Basel),2022,11(2):1-7.
Budi D S,Oktavian P,Asmarawati T P,Lestari P,Ariviani F,Ihsanulhaj R,Tsania T,Febiola D,Putri N L.Acta Med. Indones.,2022,54(4):540-555.
Singh R S P,Walker G S,Kadar E P,Cox L M,Eng H,Sharma R,Bergman A J,Van E L,Hackman F,Toussi S S,Kalgutkar A S,Obach R S.Clin. Pharmacol. Ther.,2022,112(6):1201-1206.
Guyon J,Novion M,Fulda V,Ducint D,Molimard M,Couzi L,Kaminski H,Salvo F,Bouchet S.J. Am. Soc. Mass Spectrom.,2022,33(10):1975-1981.
Sun L L,Zhang F F,Shen W B,Ding Y.J. Instrum. Anal. (孙琳琳,张芬芬,沈文斌,丁娅.分析测试学报),2016,35(9):1157-1161.
Guo Q S,Shi G Q,Song W,Xu X.J. Instrum. Anal. (郭强胜,石高旗,宋巍,许旭.分析测试学报),2012,31(1):117-120.
Zhang F F,Jiang M H,Shen W B,Ding Y.J. Nanjing Norm. Univ.:Eng. Technol. Ed. (张芬芬,蒋孟虹,沈文斌,丁娅.南京师范大学学报:工程技术版),2014,14(2):8-18.
Hu M F,Jiang M,Qiu H,Wang L J,Wei Q.J. Instrum. Anal. (胡敏芳,江明,邱慧,王玲娟,魏强.分析测试学报),2013,32(12):1511-1514.
Spelta F,Liverani L,Peluso A,Marinozzi M,Urso E,Guerrini M,Naggi A.Front. Med. (Lausanne),2019,18(6):78.
Khalil A,Kashif M.Crit. Rev. Anal. Chem.,2021,9:(1)-15.
Qiao R R,Sun J,Yang C H,Xiao Q,Cui Y X.Chin. J. Magn. Reson. 乔瑞瑞,孙静,杨春晖,肖强,崔育新.波谱学杂志),2008,(3):307-314.
Pauli G F,Jaki B U,Lankin D C.J. Nat. Prod.,2005,68:133-149.
Bharti S K,Roy R.Trends Anal. Chem.,2012,35:5-26.
The United States Pharmacopieial Convention. USP43-NF38 General Chapiter 761. Nuclear Magnetic Resonance Spectroscopy.[2023-02-10].
Malz F,Jancke H.J. Pharm. Biomed. Anal.,2005,38(5):813-823.
Shi X C,Wu X F,Xiao X Y.J. Pharm. Anal. (师小春,吴先富,肖新月.药物分析杂志),2020,40(11):1914-1922.
Zhang C Y,Huang H W,Wu J M,Yao J,Hu C Q.Chin. Pharm. J. (张才煜,黄海伟,吴建敏,姚静,胡昌勤.中国药学杂志),2015,50(19):1721-1725.
0
浏览量
8
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构